Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

29 Aug 2011

Abstract excerpt

The PI3K pathway is frequently activated in cancer; therefore, considerable effort is focused on identifying compounds that can inhibit specific pathway components, particularly the hallmark oncogene PIK3CA. Although targeted inhibition of a cancer survival gene holds significant promise, there are concerns that drug resistance may emerge within the cancerous cells, thus limiting clinical efficacy. Using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21876152
DOI: 10.1073/pnas.1108237108

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axisPMID 21876152Read ↗

Lost in translation: dysregulation of cap-dependent translation and cancer.Semantic proximity Read ↗

Reduced 4E-BP1 activity leads to acquired capivasertib resistance via increased cap-dependent protein synthesisSemantic proximity Read ↗

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancerSemantic proximity Read ↗

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer TherapySemantic proximity Read ↗

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerSemantic proximity Read ↗

Genomic Alterations in PIK3CA -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα InhibitorsSemantic proximity Read ↗

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphomaSemantic proximity Read ↗

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.Semantic proximity Read ↗

Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1Semantic proximity Read ↗

Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast CancersSemantic proximity Read ↗

Translation initiation: a critical signalling node in cancer.Semantic proximity Read ↗

PI3Kδ activates E2F1 synthesis in response to mRNA translation stressSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.